Quarterly report pursuant to Section 13 or 15(d)

Consolidated Statements of Stockholders' Equity (Unaudited)

v3.8.0.1
Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands
Total
Common Stock
Paid-in Capital
Accumulated Other Comprehensive Income (loss)
Retained Deficit
Beginning Balance (in shares) at Dec. 31, 2015   108,322,250      
Beginning Balance at Dec. 31, 2015 $ 2,038,837 $ 1,082 $ 2,824,303 $ (55,177) $ (731,371)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income (loss) (739,339)       (739,339)
Other Comprehensive Income 4,361     4,361  
Stock Compensation 9,550   9,550    
Issuance of Restricted Stock (in shares)   226,283      
Issuance of Restricted Stock 0 $ 2 (2)    
Issuance of Common Stock in public offerings, net of related expenses (in shares)   16,905,000      
Issuance of Common Stock in public offerings, net of related expenses 411,711 $ 169 411,542    
Ending Balance (in shares) at Sep. 30, 2016   125,453,533      
Ending Balance at Sep. 30, 2016 $ 1,725,120 $ 1,253 3,245,393 (50,816) (1,470,710)
Beginning Balance (in shares) at Dec. 31, 2016 158,829,816 158,829,816      
Beginning Balance at Dec. 31, 2016 $ 2,183,892 $ 1,588 3,946,442 (53,058) (1,711,080)
Increase (Decrease) in Stockholders' Equity [Roll Forward]          
Net income (loss) 278,626       278,626
Other Comprehensive Income 12,719     12,719  
Stock Compensation 7,988   7,988    
Issuance of Common Stock for the Vitruvian Acquisition, net of related expenses (in shares)   23,852,117      
Issuance of Common Stock for the Vitruvian Acquisition, net of related expenses 459,436 $ 239 459,197    
Issuance of Restricted Stock (in shares)   399,843      
Issuance of Restricted Stock $ 0 $ 4 (4)    
Ending Balance (in shares) at Sep. 30, 2017 183,081,776 183,081,776      
Ending Balance at Sep. 30, 2017 $ 2,942,661 $ 1,831 $ 4,413,623 $ (40,339) $ (1,432,454)